We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

125 hedge funds and large institutions have $3.53B invested in MoonLake Immunotherapeutics in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 51 increasing their positions, 33 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 33

32% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 28

10% more capital invested

Capital invested by funds: $3.21B → $3.53B (+$322M)

6% more funds holding

Funds holding: 118 → 125 (+7)

6.21% less ownership

Funds ownership: 105.3% → 99.09% (-6.2%)

16% less call options, than puts

Call options by funds: $39.7M | Put options by funds: $47.3M

40% less funds holding in top 10

Funds holding in top 10: 10 → 6 (-4)

Holders
125
Holders Change
+7
Holders Change %
+5.93%
% of All Funds
1.82%
Holding in Top 10
6
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-40%
% of All Funds
0.09%
New
37
Increased
51
Reduced
33
Closed
28
Calls
$39.7M
Puts
$47.3M
Net Calls
-$7.57M
Net Calls Change
+$48.7M

Top Buyers

Rank Fund Capital Flow
1
DGM
Darwin Global Management
Jersey
+$53.6M
2
Holocene Advisors
Holocene Advisors
New York
+$44.1M
3
ACA
Avoro Capital Advisors
New York
+$29.9M
4
FC
Finepoint Capital
Massachusetts
+$29M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$23.2M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$44.3M
2
RI
RTW Investments
New York
-$28.5M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$22M
4
BlackRock
BlackRock
New York
-$18.9M
5
IHAM
Integral Health Asset Management
New York
-$14.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
APM
126
Avidity Partners Management
Texas
– -$44.3M -777,172 Closed
RI
127
RTW Investments
New York
– -$28.5M -500,000 Closed
Franklin Resources
128
Franklin Resources
California
– -$12.1M -212,773 Closed
O
129
OrbiMed
New York
– -$6.67M -117,000 Closed
ACM
130
Altium Capital Management
New York
– -$5.02M -88,000 Closed
Ameriprise
131
Ameriprise
Minnesota
– -$4.95M -86,862 Closed
ACM
132
Atika Capital Management
New York
– -$4.84M -85,000 Closed
Walleye Capital
133
Walleye Capital
New York
– -$3.87M -67,926 Closed
VCIM
134
Velan Capital Investment Management
Georgia
– -$3.15M -55,300 Closed
MIM
135
Monashee Investment Management
Massachusetts
– -$2.85M -50,000 Closed
SEI Investments
136
SEI Investments
Pennsylvania
– -$1.81M -31,790 Closed
Marshall Wace
137
Marshall Wace
United Kingdom
– -$1.74M -30,451 Closed
MAP
138
Moody Aldrich Partners
Massachusetts
– -$1.46M -25,655 Closed
EI
139
EAM Investors
California
– -$1.19M -20,917 Closed
SFG
140
SVB Financial Group
Texas
– -$922K -16,173 Closed
GGHC
141
Gilder Gagnon Howe & Co
New York
– -$853K -14,959 Closed
Renaissance Technologies
142
Renaissance Technologies
New York
– -$764K -13,396 Closed
ACH
143
ArrowMark Colorado Holdings
Colorado
– -$570K -10,000 Closed
MS
144
Maven Securities
Jersey
– -$570K -10,000 Closed
OQS
145
Occudo Quantitative Strategies
Florida
– -$394K -6,918 Closed
DekaBank Deutsche Girozentrale
146
DekaBank Deutsche Girozentrale
Germany
– -$351K -6,200 Closed
Walleye Trading
147
Walleye Trading
New York
– -$309K -5,425 Closed
GCM
148
Graham Capital Management
Connecticut
– -$248K -4,352 Closed
Group One Trading
149
Group One Trading
Illinois
– -$218K -4,234 Closed
Belvedere Trading
150
Belvedere Trading
Illinois
– -$203K -3,931 Closed
3 4 5
6
7

MLTX Hedge Fund Activity: Q4 2023 in Review

125 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q4 2023, worth a combined $3.53B — up 10% from $3.21B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new MLTX positions and 28 closed out — a net gain of 9 holders — while 51 added to existing stakes and 33 trimmed.

The largest buyer was Darwin Global Management, opening a new position worth an estimated $53.6M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $44.3M sold.

  • 125 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q4 2023, up from 118 in Q3 2023.
  • Funds reported $3.53B of MoonLake Immunotherapeutics stock for Q4 2023, up 10% quarter-over-quarter.
  • 37 funds opened new MoonLake Immunotherapeutics positions in Q4 2023 and 28 closed out, a net change of +9 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q4 2023 was Darwin Global Management, an estimated $53.6M added.
  • The largest MoonLake Immunotherapeutics seller in Q4 2023 was Avidity Partners Management, an estimated $44.3M sold.

Based on aggregated 13F filings for Q4 2023.